trending Market Intelligence /marketintelligence/en/news-insights/trending/VY2XMJANRa-3fZAxTt4jfg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Soleno Therapeutics prices $13.4M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Soleno Therapeutics prices $13.4M common stock offering

Soleno Therapeutics Inc. priced an underwritten public offering to raise about $13.4 million in gross proceeds.

The Redwood City, Calif.-based company is offering 11,166,667 common shares at $1.20 apiece. Oppenheimer & Co. Inc. is the sole book-running manager for the offering while Roth Capital Partners and Laidlaw & Co. Ltd. are the co-managers.

Soleno has given the underwriters a 30-day option to purchase up to an additional 1,675,000 shares at the same price.

The company plans to use the net proceeds from the offering for the development of its products, working capital and general corporate purposes.

The offering is expected to close on or around Oct. 25, subject to conditions.

Soleno develops and commercializes novel therapeutics for treating rare diseases.